Lexaria Bioscience (LEXX) said Wednesday it received approval from the lead clinical site's human research ethics committee to begin dosing in its phase 1b, 12-week chronic study of GLP-1-H24-4 for diabetes and weight loss.
The study will feature five arms testing various DehydraTECH formulations including CBD capsules, semaglutide capsules, semaglutide combined with CBD capsules, Rybelsus tablets as control, and optional tirzepatide capsules, the company said.
Clinical test article manufacturing for all study arms is complete, with a first patient, first dose study milestone slated to be achieved in late December or January 2025, Lexaria said.
The study will take place across seven clinical sites in Australia and is expected to be recognized by the US Food and Drug Administration as a registrational phase 1b study, the company said.
Shares of Lexaria were up 3.9% in recent Wednesday trading.
Price: 2.39, Change: +0.09, Percent Change: +3.91
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。